Having received FDA approval earlier this year, the Sorin Group just announced the first implantation of its Solo Smart stentless aortic heart valve in the U.S. The fully biologic implant contains no synthetic materials and is delivered using a stent to provide support during implantation. Once the replacement valve is sutured to the aortic root, the stent is removed.
Since there’s no rigid frame as with other valves, which can influence blood flow, the device performs similar to native healthy valves. Sorin touts the improved visibility of the valve during suturing, helping to speed up the procedure time and keeping the learning curve similar to stented valves.
“I am excited to have the Sorin Solo Smart stentless valve available to my patients,” said David Heimansohn, M.D., St. Vincent Heart Center, Indianapolis, Indiana. “Solo Smart is a step forward in the treatment of aortic valve disease, as this surgical valve has superior hemodynamic performance, and is much easier to implant, requiring only a single suture line. It more resembles a native aortic valve in appearance and performance, offering the best hemodynamics during all conditions, and improving patients’ lives dramatically”, added Dr. Heimansohn.